|Table of Contents|

Analysis of the efficacy and safety of flumatinib as second-or third-line treatment for chronic myeloid leukemia in chronic phase

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 10
Page:
1860-1865
Research Field:
Publishing date:

Info

Title:
Analysis of the efficacy and safety of flumatinib as second-or third-line treatment for chronic myeloid leukemia in chronic phase
Author(s):
LI Qin1; LIN Nan2; JING Li1; WANG Xuemei1; XING Hongyun1; WU Pengqiang1; HUANG Chunlan1; LI Xiaoming1
1.Department of Hematology,the Affiliated Hospital of Southwest Medical University,Sichuan Luzhou 646000,China;2.Department of Internal Medicine,Longmatan District Hospital of Traditional Chinese Medicine,Sichuan Luzhou 646000,China.
Keywords:
flumatinib; chronic myeloid leukemia; clinical efficacy
PACS:
R733.72
DOI:
10.3969/j.issn.1672-4992.2024.10.017
Abstract:
Objective：To explore the clinical efficacy and safety of domestic flumatinib mesylate,the second generation tyrosine-kinase inhibitor (TKI),as second-or third-line treatment for patients with chronic myeloid leukemia (CML) in chronic phase (CP).Methods:From January 2020 to June 2022,38 CML-CP patients after first-or second-line TKI-therapy failure or intolerance and pursuing deep molecular response in department of hematology of a hospital received oral administration of 600 mg flumatinib once daily.The hematologic,cytogenetic and molecular responses,as well as adverse events were evaluated.Results:A total of 31 patients receiving flumatinib as second-line treatment and 7 patients of them as third-line treatment were included in this study.With a median follow-up of 33（2~42）months,the cumulative rates of complete cytogenetic response (CCyR) and major molecular response (MMR) were 78.6%(22/28),61.3%(19/31),respectively in those receiving flumatinib as second-line therapy.In the 11 patients who did not achieve CCyR before treatment,4 patients (36.4%) achieved CCyR,and in the 26 patients who did not achieve MMR,14 patients (53.8%) achieved MMR.The median follow-up was 31（9~37）months in those receiving flumatinib as third-line therapy,and 4 patients did not reach MMR before treatment,2 patients obtained MMR.In the 7 patients who pursued deep molecular reaction,6 patients achieved MR4.0 at 3~6 months after treatment and 1 patient achieved MR4.0 at 12 months after treatment.During the follow-up period,5 patients died,4 patients progressed to blast crisis within 2 to 8 months after treatment,2 patients had E255K/V mutation,1 patient had both T315I and K357R mutation,and the patients died at 4,8,9 and 10 months after treatment respectively,and 1 patient died of the second tumor at 29 months after treatment.The estimated overall survival rate at 33 months was 85.9%,and progression-free survival rate was 83.1%.Hematologic adverse reactions included grade Ⅲ-Ⅳ neutrophil in 1 case (3.3%) and grade Ⅲ-Ⅳ thrombocytopenia in 2 cases (6.7%).Non-hematological adverse reactions were mild,and no grade Ⅲ-Ⅳ adverse reactions occurred.Conclusion:Domestic flumatinib mesylate as a second-and third-line drug for the treatment of CML has a good clinical efficacy and overall safety,but more data are needed to verify its long-term efficacy and safety.

References:

[1] HOCHHAUS A,LARSON RA,GUILHOT F,et al.Long-term outcomes of imatinib treatment for chronic myeloid leukemia［J］.N Engl J Med,2017,376(10):917-927.
[2] LUO H,QUAN H,XIE C,et al.HH-GV-678,a novel selective inhibitor of Bcr-Abl,outperforms imatinib and effectively overrides imatinib resistance［J］.Leukemia,2010,24(10):1807-1809.
[3] Chinese Society of Hematology,Chinese Medical Association.The guidelines for diagnosis and treatment of chronic myelogenous leukemia in china (2020 edition)［J］.Chinese Journal of Hematology,2020,41(5):353-364.
[4] DEININGER MW,SHAH NP,ALTMAN JK,et al.Chronic myeloid leukemia,version 2.2021,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2020,18(10):1385-1415.
[5] STEEGMANN JL,CERVANTES F,LE COUTRE P,et al.Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia［J］.Leuk Lymphoma,2012,53(12):2351-2361.
[6] CAVALLO G,METRANGOLO P,MILANI R,et al.The halogen bond［J］.Chem Rev,2016,116(4):2478-2601.
[7] 蒋雅沁，王季石，肖仕珊，等.氟马替尼二线治疗2例慢性髓系白血病并文献复习［J］.重庆医学,2021,50(12):2030-2033. JIANG YQ,WANG JS,XIAO SS,et al.Flumatinib for second-line treatment in 2 cases of chronic myeloid leukemia and literature review［J］.Chongqing Medicine,2021,50(12):2030-2033.
[8] 邹秀平，杨壮志，王雅丹，等.氟马替尼克服bcr-abl1 f317l突变的慢性髓性白血病一例［J］.临床内科杂志,2022,39(10):682-683. ZHOU XP,YANG ZZ,WANG YD,et al.A case of flumatinib in the treatment of chronic myeloid leukemia with BCR-ABL1 F317L mutation［J］.Journal of Clinical Internal Medicine,2022,39(10):682-683.
[9] 郭勇鑫，陆天，陈文明，等.氟马替尼治疗伊马替尼耐药或不耐受慢性粒细胞白血病的效果及安全性［J］.白血病·淋巴瘤,2023,32(1):45-50. GUO YX,LU T,CHEN WM,et al.Efficacy and safety of flumatinib in the treatment of chronic myeloid leukemia after imatinib resistance or intolerance［J］.Journal of Leukemia and Lymphoma,2023,32(1):45-50.
[10] 张倩，齐凌，纪德香，等.氟马替尼治疗慢性粒细胞白血病患者的疗效及安全性分析［J］.中国实验血液学杂志，2023，31(04)：1014-1018. ZHANG Q,QI L,JI DX,et al.Efficacy and safety of flumatinib in treatment of patients with chronic myeloid leukemia［J］.Journal of Experimental Hematology,2023,31(04):1014-1018.
[11] HOCHHAUS A,BACCARANI M,SILVER RT,et al.European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia［J］.Leukemia,2020,34(4):966-984.
[12] 孔军，付海霞，赖悦云，等.依尼舒二线治疗慢性髓系白血病慢性期15例患者的初步临床疗效［J］.临床血液学杂志,2016,29(11):898-901. KONG J,FU HX,LAI YY,et al.Dasatinib of China Tai-tianqing as second line treatment for chronic myelogenous leukemia in chronic phase［J］.Journal of Clinical Hematology,2016,29(11):898-901.
[13] 陈怡琳，王龙，袁国林，等.国产达沙替尼二线治疗慢性髓性白血病慢性期患者的疗效和安全性分析［J］.中华血液学杂志,2019,40(2):98-104. CHEN YL,WANG L,YUAN GL,et al.Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase［J］.Chinese Journal of Hematology,2019,40(2):98-104.
[14] ZHANG L,MENG L,LIU B,et al.Flumatinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia:A phase iii,randomized,open-label,multi-center festnd study［J］.Clin Cancer Res,2021,27(1):70-77.
[15] 石大雨，秦亚溱，赖悦云，等.BCR-ABL激酶区突变在酪氨酸激酶抑制剂耐药慢性髓性白血病患者中的分布及其影响因素［J］.中华血液学杂志,2020,41(6):469-476. SHI DY,QIN YZ,LAI YY,et al.Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia［J］.Chinese Journal of Hematology,2020,41(6):469-476.

Memo

Memo:
四川省卫生和计划生育委员会重点研究项目（编号：18ZD014）；四川省泸州市科技厅重点研发项目（编号：2019-SYF-36）
Last Update: 1900-01-01